-
Corning Jereh announces 2020 full-year financial results and company progress
Time of Update: 2021-07-14
Corning Jereh Biopharmaceuticals announced the company's business progress and financial results for the full year of 2020 . Dr. Xu Ting, Chairman and President of Corning Jereh, said: "2020 is a
-
Premier Pharmaceuticals' RPI regulations experts paved the way for Chinese pharmaceutical companies to globalize
Time of Update: 2021-07-14
►One step ahead With comprehensive product development and registration experience, the RPI expert team helps customers formulate precise R&D strategies through simple and customized methods, avoid detours, and guide customers to quickly achieve their drug development goals .
-
Biocytogram announces the official change of logo
Time of Update: 2021-07-14
After solid technology and platform strength The accumulation of the new Biocytometer has given birth to the groundbreaking of Biocytometer, and Biocytometer will focus more on the research and development of innovative antibody drugs in the future .
-
WuXi Biologics has outstanding performance in 2020
Time of Update: 2021-07-14
► 40. 9% to RMB 5. 612 billion ► 52. 7% to 2. 533 billion yuan ► 67. 5% to RMB 1. 693 billion ► 45. 1% and 30. 2% ► 71. 7% to 94. 6 million U. S. dollars ► 122. 0% to 11. 32 billion U. S. dollars ►
-
Cai said the performance of Livzon Group is currently weak, can the overweight Chinese medicine sector break the situation?
Time of Update: 2021-07-14
8 billion yuan?Livzon Group stated in the announcement that the company can cooperate with Tianjin Tongrentang at the level of traditional Chinese medicine business, and can also realize corresponding investment income through its cash dividends or initial public offerings .
-
Jianxin Force completes 625 million yuan (96 million US dollars) A round of financing
Time of Update: 2021-07-14
" This round of funding will accelerate the construction of Jianxin Force in Hangzhou, China, and provide global GMP biopharmaceutical production capacity, including the establishment of cell and gene therapy production capacity and a monoclonal antibody production facility in a joint venture with Thermo Fisher .
-
Jiangxi Nature, the first proprietary Chinese medicine company in the US stock market, closed down 5% on the day of its issuance. This company has a lot of problems
Time of Update: 2021-07-14
According to the official website of the National Drug Administration, Jiangxi Nature Pharmaceutical has obtained multiple approval numbers for the production of medicines, including wind pain medicinal liquor, rheumatic pain medicinal liquor, Fuzilizhong pills, and axe-snake medicinal liquor .
-
Beat 15 rivals Amgen's $1.9 billion acquisition of Five Prime
Time of Update: 2021-07-14
On November 8th last year, the stock price of Five Prime ushered in the dawn, when the company announced the positive data of the Phase II clinical trial of bemarituzumab .
-
CStone Pharmaceuticals Announces Approval of China's First Selective RET Inhibitor, Phuket Hua
Time of Update: 2021-07-14
CStone Pharmaceuticals, a leading biopharmaceutical company that focuses on the development and commercialization of innovative tumor immunotherapy and precision treatment drugs, today announced that the National Medical Products Administration (NMPA) of China has approved Pujinghua® (Platinib Capsules) as National Class I new drug application for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) adult patients who have previously received platinum-containing chemotherapy for transfection rearrangement (RET) gene fusion positive .
-
KaVo Group Shanghai Headquarters Innovation Center of Excellence officially launched
Time of Update: 2021-07-14
Professor Wu Jianyong, director of the Department of Stomatology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, and deputy chairman of the Orthodontics Committee of the Shanghai Stomatological Association, said: “The innovation of digital dental diagnosis and treatment is inseparable from the cutting-edge training and transformation provided for doctors to provide patients with More high-quality and precise services .
-
Kangchen Pharmaceutical's net profit fell by 30%. Is it the "pot" of the epidemic or the "fruit" of a single product?
Time of Update: 2021-07-14
According to the 2020 semi-annual report of Kangchen Pharmaceutical, the operating income during the reporting period was 348 million yuan, a year-on-year decrease of 35.
053 billion yuan; and agkistrodon hemagglutinin for injection achieved revenue in 2020 Operating income was 792 million yuan, accounting for 98% of the annual revenue .
-
Ascent Pharmaceuticals Oribatinib is planned to be included in the breakthrough therapy category, and it is the first three-generation BCR-ABL inhibitor in China
Time of Update: 2021-07-14
A clinical-stage R&D enterprise dedicated to the development of innovative drugs in the treatment of tumors, hepatitis B and aging-related diseases, Yasheng Pharmaceutical announced today that th
-
After the termination of the ADC project, Biotech's second IPO of Hong Kong stocks
Time of Update: 2021-07-14
According to Biotech’s announcement, BAT8003 and BAT8001 are similar in some technical features, taking into account the current market pattern in the Trop2 ADC field Changes, there are high clinical development and market risks, so it was terminated .
-
Nature Pharmaceutical Announces Completion of Initial Public Offering
Time of Update: 2021-07-14
(NASDAQ: UPC), a Chinese manufacturer and seller of proprietary Chinese medicines, today announced that it has completed an initial public offering, issuing 5,000,000 common shares at a price of US$5 per share .
Without deducting underwriter discounts and related issuance expenses, the company's public offering raised a total of US$25 million .
-
Deck Pharmaceuticals Appoints Kevin Lynch as Chief Medical Officer
Time of Update: 2021-07-14
Kevin will be responsible for the company's clinical development strategy and management of the medical team, and will report directly to Dr.
Kevin used to serve as Vice President and Head of Clinical R&D and Medical Affairs of Celgene Asia Pacific.
-
MassMutual Securities announces that its client Nature Pharmaceuticals has completed its initial public offering
Time of Update: 2021-07-14
Without deduction of underwriter discounts and related issuance costs, the company raised a total of US$25 million in this public offering .
An electronic copy of the final prospectus related to the issuance can be obtained by contacting Vantone Securities by sending an email to IBAssistDesk@univest.
-
WuXi Biologics Announces 2020 Results
Time of Update: 2021-07-14
WuXi Biotechnology Co. , Ltd. , the world’s leading open biologics technology platform company that provides customers with end-to-end solutions for the discovery, development and production of biolo
-
Cinda Biological Announces 2020 Annual Results and Company Progress: Three new drugs are launched, four products are commercialized, and total revenue is 3.84 billion yuan
Time of Update: 2021-07-13
It is currently undergoing phase 1 clinical trials in China and the United States, and plans to obtain it in 2021 PoC (proof-of-concept data); the company has another potential best-in-class SIRPa monoclonal antibody in the same pathway in the preclinical research stage .
-
Fosun Pharma announces 2020 annual results: a number of innovations accelerate the implementation
Time of Update: 2021-07-13
Under the guidance of the "4IN" (Innovation, Integration, Internationalization, and Intelligent Intelligentization) strategy, Fosun Pharma is adhering to the development model of "innovative transformation, integrated operation, and steady growth", and strategically deploys the pharmaceutical and healthcare industry in its business areas Chain, based in China and expanding global business, direct operations include pharmaceuticals, medical devices and medical diagnosis, medical services, and through equity participation in Sinopharm Holdings, it covers the pharmaceutical business field .
-
Overseas clinical trials of core products have been suspended, Kanghong Pharmaceutical responded that the results did not meet the expectations of the regulatory authorities
Time of Update: 2021-07-13
Reporter | Zheng JieEdit | Xie Xin On the evening of March 28, Kanghong Pharmaceutical issued an announcement stating that its core product, Conbercept's overseas clinical trial project was suspended by the French ANSM (French National Agency for the Safety of Medicines and Health Products) .
